Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RMC-4630 with cobimetinib or osimertinib in solid tumors and NSCLC
NCT03989115Phase 2Completed
- Sponsor
- Revolution Medicines
- Start
- Jul 2019
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of vociprotafib in solid tumor, non-small cell lung cancer (NSCLC), sponsored by Revolution Medicines. Started Jul 2019; status: completed.
02
Drugs
vociprotafib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03989115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03989115.